Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

20131,670 citationsJournal Articlebronze Open Access

Authors

Michael Wang · The University of Texas MD Anderson Cancer Center

Simon Rule · Derriford Hospital

Peter Martin · Cornell University

André Goy · Hackensack University Medical Center

Rebecca Auer

Brad S. Kahl · University of Wisconsin–Madison

Wojciech Jurczak · Jagiellonian University

Abstract

Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 6, pp. 507-516

DOI: 10.1056/nejmoa1306220

Field-Weighted Citation Impact: 80.62